Genes Networking Analysis Applied to Immune Response in Lung Cancer

Dear Colleagues,

Lung cancer is the most frequent cause of cancer death worldwide, representing one of the most significant challenges in oncology. While targeted therapy has turned out to provide great benefits to specific molecular subtypes of non-small cell lung cancer (NSCLC), platinum-based chemotherapy is still the first line therapy for patients lacking a known driver mutation. However, in recent years, immunotherapy, specifically therapy with immune checkpoint inhibitors (ICIs), has revolutionized the therapeutic paradigm, demonstrating durable antitumor effects in different types of cancers, including lung cancer. To date, the mechanism of action of these new therapies is still under study, since only a fraction of patients benefit from ICIs, and the only known predictive biomarker, PD-L1, is insufficient to predict immunotherapy response. Thus, identifying new potential biomarkers and understanding the tumor and immune system interactions are crucial aspects for improving patients outcomes. Advanced sequencing technologies (DNA sequencing and RNA expressions) integrated with systems biology approaches are giving rise to large-scale study and can help toward the discovery of specific gene expression signatures associated with immune response in patients.

For this Special Issue, we are soliciting state-of-the-art work in genes networking analysis applied to immune response in lung cancer, in order to collect the most recent advances in this field all in one place.

Dr. Fortunato Bianconi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Lung cancer
• Systems biology
• Immune response
• Immunotherapy
• Gene networks
• Sequencing
• Immune checkpoint inhibitors
• Precision medicine
• Target therapy
• Gene expressions